TLR4 deficiency upregulates TLR9 expression and enhances irinotecan-related intestinal mucositis and late-onset diarrhoea.
Deysi Viviana Tenazoa WongRenata Brito Falcão HolandaAurilene Gomes CajadoAlessandro Maia BandeiraJorge Fernando Bessa PereiraJoice Oliveira AmorimClarice Sampaio TorresLuana Maria Moura FerreiraMarina Helena Silva LopesRoberta Taiane Germano OliveiraAnamaria Falcão PereiraRosane Oliveira Sant'AnaLarissa Mont'alverne ArrudaHoward Lopes Ribeiro-JúniorRonald Feitosa PinheiroPaulo Roberto Carvalho AlmeidaRobson Francisco CarvalhoFábio Figueiredo ChavesDuílio Reis Rocha-FilhoFernando de Queiroz CunhaRoberto Cesar Pereira Lima-JúniorPublished in: British journal of pharmacology (2021)
TLR4 deficiency upregulates TLR9 expression and enhances intestinal damage and the severity of late-onset diarrhoea during irinotecan-based treatment. Identifying patients genetically predisposed to chemotherapy-associated diarrhoea is a strategy toward precision medicine.
Keyphrases
- late onset
- toll like receptor
- inflammatory response
- early onset
- immune response
- poor prognosis
- irritable bowel syndrome
- end stage renal disease
- nuclear factor
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- oxidative stress
- prognostic factors
- radiation induced
- squamous cell carcinoma
- radiation therapy
- long non coding rna
- patient reported outcomes
- rectal cancer
- combination therapy